{"id":2075,"date":"2026-05-24T07:55:45","date_gmt":"2026-05-24T07:55:45","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/05\/24\/cladlad-time-middle-eastern-style\/"},"modified":"2026-05-24T07:55:45","modified_gmt":"2026-05-24T07:55:45","slug":"cladlad-time-middle-eastern-style","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/05\/24\/cladlad-time-middle-eastern-style\/","title":{"rendered":"CLADLad time Middle Eastern Style"},"content":{"rendered":"
Tweet<\/a><\/div>\n

ProfK is a CladLad and has been flying the flag for many years. I put this paper up as it reinforces what I was saying about breaks after anti-CD20. Someone asked me if we will ever get a chemical B cell depleters. <\/p>\n

My answer was you already have one…it’s called cladribine. But I said going cold turkey with anti-CD20 will now doubt lead to failures in some and I suggested that this would notably be in people with more active disease at the start of treatment and also in younger people. I said this because it has been seen with other medications, including cladribine and alemtuzumab. Now this study says there is about 25-30% of people who had cladribine that developed disease breakthrough. These people had more active disease before treatment, age was not an influence here. However if you think about anti-CD20 and doing a watch and wait…how many people with fail treatment even when they say on drug..However for the 75% there is real benefit<\/p>\n

Yamout B, Shatila A, Inshasi J, Hassan A, Szolics M, Hassan A, Farw A, Beriam B, Ismail G, Zeineddine M. Long-term Real-world Safety and Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis: The UAE Experience. Mult Scler Relat Disord. 2026 May 8;111:107244. doi: 10.1016\/j.msard.2026.107244.<\/p>\n

Background:\u00a0<\/strong>Although oral cladribine received approval for treating relapsing-remitting multiple sclerosis (RRMS), real-world evidence regarding its long-term effectiveness and safety in the United Arab Emirates (UAE) remains limited.<\/p>\n

Yamout B, Shatila A, Inshasi J, Hassan A, Szolics M, Hassan A, Farw A, Beriam B, Ismail G, Zeineddine M. Long-term Real-world Safety and Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis: The UAE Experience. Mult Scler Relat Disord. 2026 May 8;111:107244.<\/p>\n

Objective: <\/strong>To evaluate efficacy and safety outcomes of RRMS patients treated with cladribine tablets (CladT) and identify early predictors of response.<\/p>\n

Methods: <\/strong>This is a multicenter, observational, retrospective study of RRMS patients treated with CladT from four tertiary MS centers in the UAE. Relapses, disability worsening, occurrence of new or enlarging T2-hyperintense magnetic resonance imaging (MRI) lesions and the proportion of patients achieving no-evidence-of-disease-activity-3 (NEDA-3) status were assessed. Safety outcomes included lymphocyte counts, infections and malignancy. The association between baseline characteristics and outcomes was tested to identify potential predictors of response.<\/p>\n

Results: <\/strong>A total of 163 MS patients were included, 120 (73.6%) of whom were females. Patients were treated with CladT, with a median (IQR) follow-up of 2.0 (1.0-2.6) years. A total of 121 (74.2%) patients had received another disease-modifying therapy (DMT) before cladribine. By the end of follow-up, the mean annualized relapse rate decreased by 84.4% (p<0.001). Most patients (91.8%) showed no disability progression, 74.1% had no new MRI activity, and 70.5% achieved NEDA-3. The number of relapses prior to CladT was the only predictor of NEDA-3. Safety outcomes included 7 adverse events (2.5%), with no hospitalizations. One patient developed a malignancy (astrocytoma) 1.2 years after treatment initiation.<\/p>\n

Conclusion: <\/strong>Our study results confirm the safety and efficacy profiles of CladT reported in Phase 3 clinical trials and other real-world studies<\/p>\n

COI: Multiple<\/p>\n

Source: multiple-sclerosis-research.org<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Tweet ProfK is a CladLad and has been flying the flag for many years. I put this paper up as it reinforces what I was saying about breaks after anti-CD20. Someone asked me if we will ever get a chemical B cell depleters. My answer…<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-2075","post","type-post","status-publish","format-standard","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/2075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=2075"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/2075\/revisions"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=2075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=2075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=2075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}